Brief: Beyond Air Licenses Commercial Rights To Selective NNOS Inhibitors
15/06/2023 21:11
June 15 (Reuters) - Beyond Air Inc XAIR.O :
* BEYOND AIR® LICENSES COMMERCIAL RIGHTS TO SELECTIVE
NEURONAL
NITRIC OXIDE SYNTHASE (NNOS) INHIBITORS FOR THE TREATMENT OF
AUTISM SPECTRUM DISORDER FROM HEBREW UNIVERSITY OF JERUSALEM
* BEYOND AIR INC - PLAN TO INITIATE A FIRST-IN-HUMAN
CLINICAL
TRIAL OF NNOS FOR TREATMENT OF ASD IN 2025
Source text for Eikon: ID:nGNX5Tm6Cb
Further company coverage: XAIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyond Air
See all newsBrief: Beyond Air Enters Definitive Agreement To Sell Its NeuroNOS Stake To UNIVO Pharmaceutical Industries In Exchange For Equity And Milestone Payments
Beyond Air Inc reports results for the quarter ended June 30 - Earnings Summary
Beyond Air Q1 net loss slightly widens, reaffirms 2026 outlook
Beyond Air Inc expected to post a loss of $10.80 a share - Earnings Preview
NASDAQ RESUMED AT 04:00 AM